In the eleventh version (2024) and the third version (2025) of the NCCN Clinical Practice Guidelines for NSCLC [33], osimertinib with or without chemotherapy and amivantamab–lazertinib are listed as first-line treatments for adult patients with advanced NSCLC-harboring EGFR Exon 19 deletion or Exon 21 L858R mutations (Table 1). Here, EGFR is linked to non-small cell lung carcinoma.